Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YR 001

Next Previous
X
Search
Drug Profile

YR 001

Alternative Names: YR-001

Latest Information Update: 19 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YIRUI Pharmaceutical Technology
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Psoriasis

Most Recent Events

  • 19 Jun 2024 Phase-II clinical trials in Atopic dermatitis in USA (Topical) (NCT06309355)
  • 15 Mar 2024 Yirui Pharmaceutical Technology plans a phase II trial for Atopic dermatitis in USA (Topical) in June 2024 (NCT06309355)
  • 14 Dec 2023 Hangzhou Yirui Pharmaceutical Technology completes a phase-I trial in Psoriasis and Atopic dermatitis (In adults, In the elderly, In volunteers) in USA (Topical, Ointment) (NCT05718921)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top